Analyze Diet
Equine veterinary journal2024; 57(1); 160-168; doi: 10.1111/evj.14056

Equine uveitis: Outcome and adverse effects after one or two intravitreal low-dose gentamicin injections.

Abstract: Uveitis is common in horses, potentially turning chronic (persistent or recurrent) resulting in impaired vision or blindness. All mainstay therapeutics aims at controlling inflammation, but long-term or lifelong treatment is often needed with possibly severe side effects. Therefore, intravitreal injections with low-dose gentamicin (IVGI) have been used in attempt to give a long-lasting result with potentially less side effects. Objective: To retrospectively assess outcome and long-term complications following one or two low-dose IVGI in Swedish horses with chronic uveitis. Methods: Retrospective case series. Methods: Medical records of horses diagnosed with uveitis examined at the Equine Clinic of the University Animal Hospital of Sweden between 2016 and 2021 were reviewed. Inclusion criteria were horses with a diagnosis of chronic uveitis that were treated with 4 mg IVGI. After injection, tapering doses of anti-inflammatory medications were administered. Due to persistence or recurrence of uveitis despite IVGI, some horses received a second injection. A positive outcome was defined as controlled uveitis, despite no or minimal anti-inflammatory medication. Results: 32 eyes (29 horses) were included. Based on clinical evaluation, uveitis was classified as anterior (91%) or panuveitis (9%). 10 eyes were treated with IVGI twice. A positive outcome was observed in 13/32 eyes (41%). Inflammation in 9/32 eyes was controlled after the first, and in 4/10 eyes after the second IVGI treatment. Long-term complications included retinal degeneration in seven eyes, and mature cataracts in five eyes. Enucleations were performed in 14/32 eyes, due to lack of favourable response of IVGI, or due to complications, that is, glaucoma, corneal ulceration, and/or corneal mineralisation. One horse was euthanised due to painful bouts of inflammation in both eyes despite treatment. Conclusions: Small sample size, retrospective design with no control group, no histopathology performed, infrequent sampling for Leptospira and no standardised treatment protocol after the IVGI. Conclusions: In this group of Swedish horses, predominantly diagnosed clinically with anterior uveitis, a positive outcome was observed in 41% of eyes following one or two low-dose IVGI. Retinal degeneration in the visual streak was observed in 22% of eyes, which is a higher proportion of this complication than previously described.
Publication Date: 2024-02-08 PubMed ID: 38329024PubMed Central: PMC11616955DOI: 10.1111/evj.14056Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research aims to study the impact of one or two intravitreal injections of low-dose gentamicin (IVGI) in treating chronic uveitis in horses, and explores the long-term complications of this treatment.

Methodology

  • The researchers conducted a retrospective analysis of medical records of Swedish horses treated at the Equine Clinic of the University Animal Hospital between 2016 and 2021.
  • The inclusion criteria for the study were horses diagnosed with chronic uveitis that were treated with a 4-milligram dosage of IVGI. Some horses received a second IVGI injection due to persistence or recurrence of uveitis.
  • A “positive outcome” was defined as controlled uveitis with little to no anti-inflammatory medication.

Results

  • A total of 32 eyes from 29 horses were included in the study. Uveitis was categorized as anterior in 91% of cases and panuveitis in 9% of cases.
  • 10 eyes were treated with two doses of IVGI. A positive outcome was observed in 41% of the treated eyes. 9 of these were controlled after the first dose and 4 after the second dose.
  • Long-term complications included retinal degeneration in seven eyes and mature cataracts in five. Furthermore, 14 eyes had to be enucleated, or removed, due to adverse effects such as glaucoma, corneal ulceration, and corneal mineralisation or lack of response to the IVGI treatment. A single horse had to be euthanised because of painful recurrent bouts of eye inflammation despite undergoing the treatment.

Conclusions

  • The study had several limitations including a small sample size, lack of a control group, absence of histopathology, infrequent Leptospira sampling, and no standardised post-IVGI treatment protocol.
  • Nevertheless, among the group of Swedish horses predominantly diagnosed with anterior uveitis, it was found that 41% of eyes responded positively to one or two low-dose IVGI treatments.
  • Retinal degeneration was observed in 22% of treated eyes, a rate higher than previously described, indicating a possible adverse effect of this treatment mechanism.

Cite This Article

APA
Morén S, Kallberg M, Strom L. (2024). Equine uveitis: Outcome and adverse effects after one or two intravitreal low-dose gentamicin injections. Equine Vet J, 57(1), 160-168. https://doi.org/10.1111/evj.14056

Publication

ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 57
Issue: 1
Pages: 160-168

Researcher Affiliations

Morén, S
  • Equine Clinic, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Kallberg, M
  • Equine Clinic, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden.
Strom, L
  • Equine Clinic, University Animal Hospital, Swedish University of Agricultural Sciences, Uppsala, Sweden.

MeSH Terms

  • Animals
  • Horses
  • Horse Diseases / drug therapy
  • Uveitis / veterinary
  • Uveitis / drug therapy
  • Retrospective Studies
  • Intravitreal Injections / veterinary
  • Intravitreal Injections / adverse effects
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Female
  • Male
  • Gentamicins / administration & dosage
  • Gentamicins / adverse effects
  • Gentamicins / therapeutic use
  • Treatment Outcome

Conflict of Interest Statement

The authors have no competing interests to declare.

References

This article includes 40 references
  1. Gilger BC, Michau TM. Equine recurrent uveitis: new methods of management.. Vet Clin North Am Equine Pract 2004;20(2):417–427. vii.
    pubmed: 15271431
  2. Schwink KL. Equine uveitis.. Vet Clin North Am Equine Pract 1992;8(3):557–574.
    pubmed: 1458329
  3. Gilger B. Equine recurrent uveitis: the viewpoint from the USA.. Equine Vet J 2010;42(S37):57–61.
    pubmed: 20939168
  4. Gerding JC, Gilger BC. Prognosis and impact of equine recurrent uveitis.. Equine Vet J 2016;48(3):290–298.
    pubmed: 25891653
  5. Gilger BC, Wilkie DA, Clode AB, McMullen RJ Jr, Utter ME, Komaromy AM. Long‐term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis.. Vet Ophthalmol 2010;13(5):294–300.
    pubmed: 20840106
  6. Dwyer AE, Crockett R, Kalsow CM. Association of leptospiral seroreactivity and breed with uveitis and blindness in horses: 372 cases (1986‐1993).. J Am Vet Med Assoc 1995;207(10):1327–1331.
    pubmed: 7591929
  7. Deeg CA. Ocular immunology in equine recurrent uveitis.. Vet Ophthalmol 2008;11:61–65.
    pubmed: 19046272
  8. Malalana F, Stylianides A, McGowan C. Equine recurrent uveitis: human and equine perspectives.. Vet J 2015;206(1):22–29.
    pubmed: 26188862
  9. Gilger BC, Malok E, Stewart T, Horohov D, Ashton P, Smith T. Effect of an intravitreal cyclosporine implant on experimental uveitis in horses.. Vet Immunol Immunopathol 2000;76(3–4):239–255.
    pubmed: 11044557
  10. Pinto NI, McMullen RJ, Linder KE, Cullen JM, Gilger BC. Clinical, histopathological and immunohistochemical characterization of a novel equine ocular disorder: heterochromic iridocyclitis with secondary keratitis in adult horses.. Vet Ophthalmol 2015;18(6):443–456.
    pubmed: 25399915
  11. McMullen RJ Jr, Fischer BM. Medical and surgical management of equine recurrent uveitis.. Vet Clin North Am Equine Pract 2017;33(3):465–481.
    pubmed: 28985983
  12. Spiess B. Equine recurrent uveitis: the European viewpoint.. Equine Vet J 2010;42(S37):50–56.
    pubmed: 20939167
  13. Fruèhauf B, Ohnesorge B, Deegen E, Boeve M. Surgical management of equine recurrent uveitis with single port pars plana vitrectomy.. Vet Ophthalmol 1998;1(2–3):137–151.
    pubmed: 11397223
  14. Gerhards H, Wollanke B, Brem S. Vitrectomy as a diagnostic and therapeutic approach for equine recurrent uveitis (ERU).. Proc Am Assoc Equine Practnrs 1999;45:89–93.
  15. Toemoerdy E, Haessig M, Spiess BM. The outcome of pars plana vitrectomy in horses with equine recurrent uveitis with regard to the presence or absence of intravitreal antibodies against various serovars of Leptospira interrogans.. Pferdeheilkunde 2010;26(2):251–254.
  16. Gilger BC, Wilkie DA, Davidson MG, Allen JB. Use of an intravitreal sustained‐release cyclosporine delivery device for treatment of equine recurrent uveitis.. Am J Vet Res 2001;62(12):1892–1896.
    pubmed: 11763177
  17. Pinard C, Piètrement E, Macieira S, Tremblay D. Intravitreal injections of gentamicin for the treatment of Leptospira‐associated equine recurrent uveitis.. 36th Annual Meeting of the ACVO; Nashville, TN 2005.
  18. Fischer BM, McMullen RJ, Reese S, Brehm W. Intravitreal injection of low‐dose gentamicin for the treatment of recurrent or persistent uveitis in horses: preliminary results.. BMC Vet Res 2019;15(1):1–12.
    pmc: PMC6335700pubmed: 30651102
  19. Launois T, González Hilarión LM, Barbe F, Leurquin C, Bihin B, Hontoir F. Use of intravitreal injection of gentamicin in 71 horses with equine recurrent uveitis.. J Equine Vet 2019;77:93–97.
    pubmed: 31133325
  20. Kleinpeter A, Goepfert A, Koehler E, Brehm W. Intravitreal injection of low‐dose gentamicin for the treatment of ERU‐affected horses.. Tieraerztliche Praxis Ausgabe Grosstiere Nutztiere 2019;47(1):25–34.
    pubmed: 30808028
  21. Smith HL, Berglund AK, Robertson JB, Schnabel LV, McMullen RJ Jr, Gilger BC. Effect of gentamicin on CD3+ T‐lymphocyte proliferation for treatment of equine recurrent uveitis: an in vitro study.. Vet Ophthalmol 2023;26(4):347–354.
    pubmed: 37116984
  22. Peyman GA, May DR, Ericson ES, Apple D. Intraocular injection of gentamicin: toxic effects and clearance.. Arch Ophthalmol 1974;92(1):42–47.
    pubmed: 4835976
  23. McDonald HR, Schatz H, Allen AW, Chenoweth RG, Cohen HB, Crawford JB. Retinal toxicity secondary to intraocular gentamicin injection.. Ophthalmology 1986;93(7):871–877.
    pubmed: 3763130
  24. Burkholder BM, Jabs DA. Uveitis for the non‐ophthalmologist.. BMJ 2021;372:m4979.
    pubmed: 33536186
  25. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis.. Ophthalmology 2005;112(11):1916. e1‐7.
    pubmed: 16171868
  26. Nguyen QD, Ibrahim MA, Watters A, Bittencourt M, Yohannan J, Sepah YJ. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non‐infectious uveitis: primary 6‐month results of the SAVE study.. J Ophthalmic Inflamm Infect 2013;3(1):1–15.
    pmc: PMC3610181pubmed: 23514595
  27. Nguyen QD, Merrill PT, Sepah YJ, Ibrahim MA, Banker A, Leonardi A. Intravitreal sirolimus for the treatment of noninfectious uveitis: evolution through preclinical and clinical studies.. Ophthalmology 2018;125(12):1984–1993.
    pubmed: 30060978
  28. Özkiris A. Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis.. Ocul Immunol Inflamm 2006;14(4):233–238.
    pubmed: 16911985
  29. Petroutsos G, Savoldelli M, Pouliquen Y. The effect of gentamicin on the corneal endothelium An experimental study.. Cornea 1990;9(1):62–65.
    pubmed: 2297996
  30. Verma A, Stevenson B, Adler B. Leptospirosis in horses.. Vet Microbiol 2013;167(1–2):61–66.
    pubmed: 23647816
  31. Williams RD, Morter RL, Freeman MJ, Lavignette AM. Experimental chronic uveitis – ophthalmic signs following equine leptospirosis.. Invest Ophthalmol 1971;10(12):948.
    pubmed: 5128770
  32. Frellstedt L. Equine recurrent uveitis: a clinical manifestation of leptospirosis.. Equine Vet Educ 2009;21(10):546–552.
  33. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA. Leptospirosis: a zoonotic disease of global importance.. Lancet Infect Dis 2003;3(12):757–771.
    pubmed: 14652202
  34. Baverud V, Gunnarsson A, Engvall EO, Franzen P, Egenvall A. Leptospira seroprevalence and associations between seropositivity, clinical disease and host factors in horses.. Acta Vet Scand 2009;51:15.
    pmc: PMC2679755pubmed: 19331656
  35. SVA NVI. Leptospiros hos häst.. 2022.
  36. Thomas T, Galiani D, Brod R. Gentamicin and other antibiotic toxicitiy.. Ophthalmol Clin North Am 2001;14(4):611–624.
    pubmed: 11787741
  37. Brown GC, Eagle RC, Shakin EP, Gruber M, Arbizio VV. Retinal toxicity of intravitreal gentamicin.. Arch Ophthalmol 1990;108(12):1740–1744.
    pubmed: 2256847
  38. Gilger BC, Reeves KA, Salmon JH. Ocular parameters related to drug delivery in the canine and equine eye: aqueous and vitreous humor volume and scleral surface area and thickness.. Vet Ophthalmol 2005;8(4):265–269.
    pubmed: 16008707
  39. Brooks D. Calcium degeneration and ocular surface failure in the horse.. Equine Vet Educ 2012;24(1):8–11.
  40. Berryhill EH, Thomasy SM, Kass PH, Reilly CM, Good KL, Hollingsworth SR. Comparison of corneal degeneration and calcific band keratopathy from 2000 to 2013 in 69 horses.. Vet Ophthalmol 2017;20(1):16–26.
    pubmed: 26773714